Eli Lilly's Phase 1b Heart-2 trial showed that a single intravenous dose of VERVE-102 significantly lowered PCSK9 protein and LDL cholesterol (LDL-C) in patients at high risk for cardiovascular disease, with reductions lasting up to 18 months. The treatment mimics natural genetic variants that protect against heart disease by turning off the PCSK9 gene in the liver. VERVE-102 was well tolerated with no serious side effects, and Lilly plans to start Phase 2 trials by the end of 2026. This new gene editing approach could transform heart disease management from chronic medication to a one-time treatment.
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
Eli Lilly reported positive Phase 3 trial results for retatrutide, a triple hormone drug targeting obesity. Patients on the highest 12 mg dose lost an average of 28.3% of their body weight, with significant improvements in cardiovascular risk markers...
Eli Lilly announced it will present important clinical trial data at the 2026 ASCO Annual Meeting, including Phase 3 results for Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive non-small cell lung cancer and Verzenio (abemaciclib) ...
Eli Lilly reported a 55.5% revenue increase in Q1 2026, driven by strong sales of Mounjaro and Zepbound. Despite this growth and raised full-year guidance, shares have fallen due to pricing pressures from China and the U.S., and competition from Novo...
